Skip to main content
SpringerLink
Log in

Quality of Life and Treatment Satisfaction among Patients with Psoriasis and Psoriatic Arthritis and Patients with Psoriasis Only

Results of the 2005 Spring US National Psoriasis Foundation Survey

  • Original Research Article
  • QOL and Treatment Satisfaction in Patients with Psoriasis with or without Psoriatic Arthritis
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Introduction: Five to forty percent of patients with cutaneous psoriasis develop an inflammatory, oligoarticular spondyloarthropathy known as psoriatic arthritis.

Objective: To compare health-related quality of life (QOL) between cutaneous psoriatic patients with and without psoriatic arthritis.

Method: Secondary cross-sectional analysis of data obtained from the 2005 Spring US National Psoriasis Foundation Quality of Life Telephone/Internet Survey. 426 patients with psoriasis and/or psoriatic arthritis were included in the 2005 survey. Among these respondents, the self-reported disease histories of 140 patients with cutaneous psoriasis and psoriatic arthritis were compared with those of 278 patients with cutaneous psoriasis only. Both groups were compared with respect to demographics, skin disease severity, treatment history and satisfaction, and QOL using previously validated assessment scales.

Results: Compared with those with skin psoriasis only, respondents with cutaneous psoriasis and psoriatic arthritis were slightly older, more likely to be female and members of the National Psoriasis Foundation, and more likely to report a younger age of disease onset. They were also more likely to be unemployed, to report their job was affected by their condition, and to report a higher mean estimate of lost annual wages. On both univariate and multivariate analysis, however, no significant differences between groups were detected in skin disease severity, overall QOL, and satisfaction with current treatment options. At the same time, individuals with skin psoriasis and psoriatic arthritis were more likely to be taking systemic agents. They also reported higher mean scores for pain, while those with cutaneous psoriasis reported higher mean scores for self-consciousness only.

Conclusion: In contrast to previous reports that did not control for skin disease severity, this study demonstrates that patients with cutaneous psoriasis and psoriatic arthritis do not report significantly worse health-related QOL compared with patients with cutaneous psoriasis only. Nor do they report significantly greater dissatisfaction with current treatment options. These findings may reflect the intrinsic inadequacy of the QOL instruments used in this study for capturing the additional burden of joint disease. Alternatively, these findings may reflect the existence of a threshold of joint disease in patients with skin psoriasis and psoriatic arthritis below which joint symptoms are perceived as negligible relative to cutaneous disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Mease PJ, Menter AM. Quality of life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2005 54: 685–704

    Article  Google Scholar 

  2. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003 49 Suppl.: S57–61

    Article  Google Scholar 

  3. Weiss SC, Kimball AB, Liewehr DJ. Quantifying the harmful effects of psoriasis on health-related quality of life. J Am Acad Dermatol 2002 47: 512–8

    Article  PubMed  Google Scholar 

  4. Husted JA, Gladman DD, Farewell VT. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001 45: 151–8

    Article  PubMed  CAS  Google Scholar 

  5. Krueger G, Koo J, Lebwohl M. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 137 (3): 280–4

    PubMed  CAS  Google Scholar 

  6. Kimball AB, Jacobson C, Weiss S. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005 6 (6): 383–92

    Article  PubMed  Google Scholar 

  7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19: 210–6

    Article  PubMed  CAS  Google Scholar 

  8. Gladman DD, Helliwell P, Mease PJ. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004 50 (1): 24–35

    Article  PubMed  Google Scholar 

  9. O’Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. BMJ 1996 313: 919–21

    Article  PubMed  Google Scholar 

  10. Kay L, Myers A, Walker D. Effects of inflammatory arthritis on quality of life in patients with psoriasis. Arch Dermatol 2003 Dec; 139 (12): 1655

    Article  PubMed  Google Scholar 

  11. Lundberg L, Johannesson M, Silverdahl M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000 80 (6): 430–4

    Article  PubMed  CAS  Google Scholar 

  12. Zachariae H, Zachariae R, Blomqvist K. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm Venereol 2002 82 (2): 108–13

    Article  PubMed  Google Scholar 

  13. Koo J, Kozma CM, Reinke K. The development of a disease-specific questionnaire to assess the quality of life for psoriasis patients: an analysis of the reliability, validity, and responsiveness of the psoriasis quality of life questionnaire. Dermatol Psychosom 2002 3: 171–9

    Article  Google Scholar 

  14. Koo J, Kozma CM, Menter A. Development of the 12 item Psoriasis Quality of Life Questionnaire (PQOL) [poster no. 606]. 61st annual meeting of the American Academy of Dermatology; 2003 Mar 21-26; San Francisco (CA)

    Google Scholar 

  15. Krueger GG, Feldman SR, Camisa C. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43 (2 Pt 1): 281–5

    Article  PubMed  CAS  Google Scholar 

  16. Nijsten T, Rolstad T, Feldman SR. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol 2005 141 (1): 19–26

    Article  PubMed  Google Scholar 

  17. Symmons DP, Lunt M, Watkins G. Developing classification criteria for peripheral joint psoriatic arthritis: step I. Establishing whether the rheumatologist’s opinion on the diagnosis can be used as the “gold standard” J Rheumatol 2006 33 (3): 552–7

    Google Scholar 

  18. Stamm TA, Nell V, Mathis M. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum 2007 57 (3): 487–94

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was made possible in part by a clinical trials grant from Centocor, Inc., and data were acquired from the 2005 Spring US National Psoriasis Foundation Survey with permission. Neither entity was involved, however, in the study design, preparation of the manuscript, data analysis, or the decision to submit for publication. This study is an accurate representation of our secondary interpretation of the data. We thank Dr Hang Lee for assistance with our statistical analysis.

Dr David Ciocon was funded by a 1-year fellowship grant from Centocor, Inc. Dr Alexa Kimball has received research and consulting support from Centocor, Connetics, Cytochroma, Genentech, Amgen, and Abbot, and is on the Medical Board of the US National Psoriasis Foundation. Dr Elizabeth Horn is a former Research Director of the US National Psoriasis Foundation.

Author information

Authors and Affiliations

  1. Department of Dermatology, Albert Einstein College of Medicine, Bronx, New York, USA

    David H. Ciocon

  2. National Psoriasis Foundation, Portland, Oregon, USA

    Elizabeth J. Horn

  3. Clinical Unit for Research Trials in Skin, Harvard Medical School, Boston, Massachusetts, USA

    Alexa B. Kimball

Authors
  1. David H. Ciocon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth J. Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexa B. Kimball
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexa B. Kimball.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ciocon, D.H., Horn, E.J. & Kimball, A.B. Quality of Life and Treatment Satisfaction among Patients with Psoriasis and Psoriatic Arthritis and Patients with Psoriasis Only. Am J Clin Dermatol 9, 111–117 (2008). https://doi.org/10.2165/00128071-200809020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200809020-00004

Keywords

Search

Navigation